Neoadjuvant use of ipilimumab in locally advanced melanoma

Howie, Lynn; Tyler, Douglas S.; Salama, April K.S.

doi:10.1002/jso.24079

Cited by 12 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several studies examining the role of neoadjuvant therapy in the setting of technically resectable disease that have shown some promising results that may change the paradigm for some patients. 67–69 An entire separate review of the neoadjuvant approach appears in this Seminar by Michael Lowe and colleagues. In the decision regarding use of a neoadjuvant approach versus surgery followed by adjuvant therapy, again research and biomarkers to further characterize risk of recurrence may help individualize treatment plans.…”

Section: Applying Trial Results To Clinical Practicementioning

confidence: 99%

See 1 more Smart Citation

Updates in adjuvant systemic therapy for melanoma

Kwak

Farrow

Salama

et al. 2018

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stage III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of Stage III and IV melanoma patients. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.

show abstract

Section: Applying Trial Results To Clinical Practicementioning

confidence: 99%

“…There are several studies examining the role of neoadjuvant therapy in the setting of technically resectable disease that has shown some promising results that may change the paradigm for some patients . An entire separate review of the neoadjuvant approach appears in this Seminar by Michael Lowe and colleagues.…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

Updates in adjuvant systemic therapy for melanoma

Kwak

Farrow

Salama

et al. 2018

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, in a pooled clinical analysis of four ongoing clinical trials (NCT02437279, NCT02231775, NCT02519322, NCT01972347) from the International Neoadjuvant Melanoma Consortium, 21 patients received either neoadjuvant combined nivolumab/ipilimumab or nivolumab alone; eight complete responses with no recurrence were observed, and only three of the 13 remaining patients had recurring disease after neoadjuvant immunotherapy with surgery (35). The benefit of ipilimumab as neoadjuvant therapy has also been reported in case studies (36,37).…”

Section: Neoadjuvant Immunotherapy In Other Tumor Typesmentioning

confidence: 85%

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer

Yeh¹,

Marrone²,

Forde³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Lung cancer continues to be the leading cause of cancer death worldwide. Recently, immunotherapy for non-small cell lung cancer (NSCLC) has emerged as a powerful treatment option for advanced lung cancer. The relative success of programmed death 1 (PD-1) and/or programmed death ligand 1 (PD-L1) antibodies in metastatic disease have increased interest in expanding their use to earlier stage NSCLC. The complex and diverse nature of stage III disease also invites the incorporation of immunotherapy into treatment plans in both the neoadjuvant and consolidation settings. Currently available data of anti-PD-(L)1 therapies in stage III NSCLC are limited. However, interim results from two studies are encouraging: a phase II neoadjuvant nivolumab trial demonstrated early signals of efficacy, and the phase III PACIFIC trial of durvalumab recently showed significant improvement in progression-free survival (PFS). Preliminary results for the phase II DETERRED trial of durvalumab have also been reported. Many studies are testing anti-PD-(L)1 therapies in the neoadjuvant and consolidation settings for stage III NSCLC, and will be discussed. As these studies mature they may provide further treatment options in management of stage III NSCLC.

show abstract

“…Melphalan ILI in combination with intra-lesional agents, such as T-VEC or PV-10 for instance, can enhance response due to the so-called bystander effect, caused by the tumour antigen release and T cell activation by the immunological reaction caused by the intra-lesional agent [57]. Immune checkpoint inhibitors have improved the prognosis for patients with locally advanced melanoma, making ILI plus checkpoint inhibition a potential novel therapeutic strategy for patients with limb melanoma [45,61]. Moreover, doxorubicin ILI combined with external beam radiotherapy has the potential to increase local disease control [62].…”

Section: Novel Isolated Limb Infusion Regimensmentioning

confidence: 99%

Molecular Aspects of the Isolated Limb Infusion Procedure

et al. 2021

View full text Add to dashboard Cite

For decades, isolated limb infusion (ILI) and hyperthermic isolated limb perfusion (HILP) have been used to treat melanoma in-transit metastases and unresectable sarcoma confined to the limb utilizing the effect of loco-regional high-dose chemotherapy to the isolated limb. Both procedures are able to provide high response rates in patients with numerous or bulky lesions in whom other loco-regional treatments are becoming ineffective. In comparison to systemic therapies, on the other hand, ILI and HILP have the advantage of not being associated with systemic side-effects. Although in principle ILI and HILP are similar procedures, ILI is technically simpler to perform and differs from HILP in that it takes advantage of the hypoxic and acidotic environment that develops in the isolated limb, potentiating anti-tumour activity of the cytotoxic agents melphalan +/− actinomycin-D. Due to its simplicity, ILI can be used in both preclinical and clinical studies to test new cytotoxic regimens and combinations with the aim to overcome tumour resistance. In the future, administration of cytotoxic agents by ILI, in combination with systemic treatments such as BRAF/MEK/KIT inhibitors, immunotherapy (CTLA-4 blockade), and/or programmed death (PD-1) pathway inhibitors, has the potential to improve responses further by inducing increased tumour cell death while limiting the ability of the tumour to suppress the immune response.

show abstract

Neoadjuvant use of ipilimumab in locally advanced melanoma

Cited by 12 publications

References 15 publications

Updates in adjuvant systemic therapy for melanoma

Updates in adjuvant systemic therapy for melanoma

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer

Molecular Aspects of the Isolated Limb Infusion Procedure

Contact Info

Product

Resources

About